In vivo inferiority of generic product compared with branded vancomycin: A paradigm shift

Therapeutic Drug Monitoring

Volumn 34, Issue 1, 2012, Pages 2-3

  'T Jong, G W ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

BACTERICIDAL ACTIVITY; BIOEQUIVALENCE; COST CONTROL; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; NOTE; PATIENT COMPLIANCE; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; UNITED KINGDOM; UNITED STATES; WORLD HEALTH ORGANIZATION; ANIMAL; ECONOMICS; MICROBIOLOGY; MOUSE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THERAPEUTIC EQUIVALENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUGS, GENERIC; HUMANS; MICE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THERAPEUTIC EQUIVALENCY; VANCOMYCIN;

EID: 84856100078     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318243e739     Document Type: Note

References (19)

1. U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. March 2003.
2. European Medicines Agency Committee for Proprietary Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. CPMP/EWP/QWP/ 1401/98. July 2001.
3. Lewek P, Kardas P. Generic drugs: The benefits and risks of making the switch. J Fam Pract. 2010;59:634-640.
4. Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure. 2006;15:165-176.
5. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003;25:2875-2890. (Pubitemid 37510596)
6. Meredith PA. Potential concerns about generic substitution: Bioequivalence versus therapeutic equivalence of different amlodipine salt forms. Curr Med Res Opin. 2009;25:2179-2189.
7. Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: Are they a good thing? Br J Clin Pharmacol. 2010;70: 335-341.
8. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence and use of generic drug therapies. Am J Manag Care. 2009;15:450-456.
9. Van Wijk BLG, Klungel OH, Heerdink ER, de Boer A. Generic substitution of antihypertensive drugs: Does it affect adherence? Ann Pharmacother. 2006;40:15-20. (Pubitemid 43221468)
10. Nation RL, Sansom LN. Bioequivalence requirements for generic products. Pharmacol Ther. 1994;62:41-55. (Pubitemid 24234857)
11. Strom BL. Generic drug substitution revisited. N Engl J Med. 1987;316:1456-1462. (Pubitemid 17079094)
12. Peterson GM. Generic substitution: A need for clarification. Br J Clin Pharmacol. 2011;71: 966-967; author reply 968.
13. Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med. 2008; 359:2674-2684.
14. Dodd S, Besag FMC. Lessons from contaminated heparin. Curr Drug Saf. 2009;4:1.
15. Verbeeck RK, Kanfer I, Walker RB. Generic substitution: The use of medicinal products containing different salts and implications for safety and efficacy. Eur J Pharm Sci. 2006;28:1-6.
16. Vesga O, Agudelo M, Salazar BE, et al. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother. 2010;54:3271-3279.
17. Zuluaga AF, Agudelo M, Cardeno JJ, et al. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PLoS ONE. 2010;5:e10744.
18. Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin. BMC Infect Dis. 2010;10:153.
19. Garćia-Arieta A. The failure to show bioequivalence is not evidence against generics. Br J Clin Pharmacol. 2010;70:452-453.